Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead

KRAS is one of the most commonly mutated oncogenes in cancers and therapeutics directly targeting the KRas have been challenging. Among the different known mutants, KRas(G12C) has been proved to be successfully targeted recently. Several covalent inhibitors selectively targeting KRas(G12C) have show...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui-yu, Qi, Wei-liang, Wang, Yu-xiang, Meng, Ling-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201555/
https://www.ncbi.nlm.nih.gov/pubmed/37223497
http://dx.doi.org/10.1016/j.gendis.2021.08.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201555/
https://www.ncbi.nlm.nih.gov/pubmed/37223497
http://dx.doi.org/10.1016/j.gendis.2021.08.011

Ejemplares similares